Low incidence of neoplasia in heart and heart-lung transplant recipients receiving triple-drug immunosuppression

M. T. Olivari, R. A. Diekmann, S. H. Kubo, E. Braunlin, S. W. Jamieson, W. S. Ring

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The risk of neoplasias developing after solid organ transplantation is markedly increased by immunosuppressive therapy. Lymphoma has been reported to develop in 13% of heart and in 33% of heart-lung transplant recipients treated with cyclosporine, and the incidence of skin carcinoma ranges between 6% and 16%. The incidence of posttransplant neoplasias with the use of lower loading and maintenance doses of cyclosporine as used in triple-drug immunosuppression is unknown. From December 1983 through August 1988, 134 heart and seven heart-lung transplants were performed at the University of Minnesota. All patients received a combination of cyclosporine, azathioprine, and prednisone. Survival was 94% at 1 and 90% at 3 years in heart recipients. Probability of acute rejection was 9% at 3 months and 12% at 1 and 3 years. B-cell lymphoma developed after heart transplant in only two patients for an incidence of 1.5%. Episodes of acute rejection and mean cyclosporine blood level did not predict the occurrence of posttransplant lymphoma. The incidence of skin carcinoma was 6.4%. No neoplasia occurred in heart-lung transplant recipients. All neoplasias were observed in patients older than 50 years. Our data indicate that the risk for developing lymphoproliferative disorders, but not for basal cell carcinoma, is reduced in heart and heart-lung transplant recipients receiving triple-drug immunosuppression. Older recipients may be at increased risk, suggesting that lower doses of immunosuppressive therapy should be considered in this group.

Original languageEnglish (US)
Pages (from-to)618-621
Number of pages4
JournalJournal of Heart Transplantation
Volume9
Issue number6
StatePublished - 1990

Fingerprint

Immunosuppression
Lung
Incidence
Pharmaceutical Preparations
Neoplasms
Cyclosporine
Immunosuppressive Agents
Lymphoma
Carcinoma
Transplants
Transplant Recipients
Skin
Lymphoproliferative Disorders
Basal Cell Carcinoma
Azathioprine
Organ Transplantation
B-Cell Lymphoma
Prednisone
Survival
Therapeutics

ASJC Scopus subject areas

  • Transplantation

Cite this

Low incidence of neoplasia in heart and heart-lung transplant recipients receiving triple-drug immunosuppression. / Olivari, M. T.; Diekmann, R. A.; Kubo, S. H.; Braunlin, E.; Jamieson, S. W.; Ring, W. S.

In: Journal of Heart Transplantation, Vol. 9, No. 6, 1990, p. 618-621.

Research output: Contribution to journalArticle

Olivari, M. T. ; Diekmann, R. A. ; Kubo, S. H. ; Braunlin, E. ; Jamieson, S. W. ; Ring, W. S. / Low incidence of neoplasia in heart and heart-lung transplant recipients receiving triple-drug immunosuppression. In: Journal of Heart Transplantation. 1990 ; Vol. 9, No. 6. pp. 618-621.
@article{45d6454b461c4430ba8c1031a8b71d93,
title = "Low incidence of neoplasia in heart and heart-lung transplant recipients receiving triple-drug immunosuppression",
abstract = "The risk of neoplasias developing after solid organ transplantation is markedly increased by immunosuppressive therapy. Lymphoma has been reported to develop in 13{\%} of heart and in 33{\%} of heart-lung transplant recipients treated with cyclosporine, and the incidence of skin carcinoma ranges between 6{\%} and 16{\%}. The incidence of posttransplant neoplasias with the use of lower loading and maintenance doses of cyclosporine as used in triple-drug immunosuppression is unknown. From December 1983 through August 1988, 134 heart and seven heart-lung transplants were performed at the University of Minnesota. All patients received a combination of cyclosporine, azathioprine, and prednisone. Survival was 94{\%} at 1 and 90{\%} at 3 years in heart recipients. Probability of acute rejection was 9{\%} at 3 months and 12{\%} at 1 and 3 years. B-cell lymphoma developed after heart transplant in only two patients for an incidence of 1.5{\%}. Episodes of acute rejection and mean cyclosporine blood level did not predict the occurrence of posttransplant lymphoma. The incidence of skin carcinoma was 6.4{\%}. No neoplasia occurred in heart-lung transplant recipients. All neoplasias were observed in patients older than 50 years. Our data indicate that the risk for developing lymphoproliferative disorders, but not for basal cell carcinoma, is reduced in heart and heart-lung transplant recipients receiving triple-drug immunosuppression. Older recipients may be at increased risk, suggesting that lower doses of immunosuppressive therapy should be considered in this group.",
author = "Olivari, {M. T.} and Diekmann, {R. A.} and Kubo, {S. H.} and E. Braunlin and Jamieson, {S. W.} and Ring, {W. S.}",
year = "1990",
language = "English (US)",
volume = "9",
pages = "618--621",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Low incidence of neoplasia in heart and heart-lung transplant recipients receiving triple-drug immunosuppression

AU - Olivari, M. T.

AU - Diekmann, R. A.

AU - Kubo, S. H.

AU - Braunlin, E.

AU - Jamieson, S. W.

AU - Ring, W. S.

PY - 1990

Y1 - 1990

N2 - The risk of neoplasias developing after solid organ transplantation is markedly increased by immunosuppressive therapy. Lymphoma has been reported to develop in 13% of heart and in 33% of heart-lung transplant recipients treated with cyclosporine, and the incidence of skin carcinoma ranges between 6% and 16%. The incidence of posttransplant neoplasias with the use of lower loading and maintenance doses of cyclosporine as used in triple-drug immunosuppression is unknown. From December 1983 through August 1988, 134 heart and seven heart-lung transplants were performed at the University of Minnesota. All patients received a combination of cyclosporine, azathioprine, and prednisone. Survival was 94% at 1 and 90% at 3 years in heart recipients. Probability of acute rejection was 9% at 3 months and 12% at 1 and 3 years. B-cell lymphoma developed after heart transplant in only two patients for an incidence of 1.5%. Episodes of acute rejection and mean cyclosporine blood level did not predict the occurrence of posttransplant lymphoma. The incidence of skin carcinoma was 6.4%. No neoplasia occurred in heart-lung transplant recipients. All neoplasias were observed in patients older than 50 years. Our data indicate that the risk for developing lymphoproliferative disorders, but not for basal cell carcinoma, is reduced in heart and heart-lung transplant recipients receiving triple-drug immunosuppression. Older recipients may be at increased risk, suggesting that lower doses of immunosuppressive therapy should be considered in this group.

AB - The risk of neoplasias developing after solid organ transplantation is markedly increased by immunosuppressive therapy. Lymphoma has been reported to develop in 13% of heart and in 33% of heart-lung transplant recipients treated with cyclosporine, and the incidence of skin carcinoma ranges between 6% and 16%. The incidence of posttransplant neoplasias with the use of lower loading and maintenance doses of cyclosporine as used in triple-drug immunosuppression is unknown. From December 1983 through August 1988, 134 heart and seven heart-lung transplants were performed at the University of Minnesota. All patients received a combination of cyclosporine, azathioprine, and prednisone. Survival was 94% at 1 and 90% at 3 years in heart recipients. Probability of acute rejection was 9% at 3 months and 12% at 1 and 3 years. B-cell lymphoma developed after heart transplant in only two patients for an incidence of 1.5%. Episodes of acute rejection and mean cyclosporine blood level did not predict the occurrence of posttransplant lymphoma. The incidence of skin carcinoma was 6.4%. No neoplasia occurred in heart-lung transplant recipients. All neoplasias were observed in patients older than 50 years. Our data indicate that the risk for developing lymphoproliferative disorders, but not for basal cell carcinoma, is reduced in heart and heart-lung transplant recipients receiving triple-drug immunosuppression. Older recipients may be at increased risk, suggesting that lower doses of immunosuppressive therapy should be considered in this group.

UR - http://www.scopus.com/inward/record.url?scp=0025615011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025615011&partnerID=8YFLogxK

M3 - Article

C2 - 2277297

AN - SCOPUS:0025615011

VL - 9

SP - 618

EP - 621

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 6

ER -